Myriad GeneticsMYGN
MYGN
About: Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Employees: 2,700
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
402% more call options, than puts
Call options by funds: $854K | Put options by funds: $170K
43% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 28
4% more funds holding
Funds holding: 219 [Q4 2024] → 228 (+9) [Q1 2025]
1.37% more ownership
Funds ownership: 101.47% [Q4 2024] → 102.84% (+1.37%) [Q1 2025]
3% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 77
34% less capital invested
Capital invested by funds: $1.27B [Q4 2024] → $833M (-$434M) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$6
48%
upside
Avg. target
$7.67
89%
upside
High target
$10
147%
upside
6 analyst ratings
3 positive
50%
3 neutral
50%
0 negative
0%
Scotiabank Sung Ji Nam | 48%upside $6 | Sector Perform Downgraded | 21 May 2025 |
Piper Sandler Dave Weiner | 122%upside $9 | Overweight Maintained | 15 May 2025 |
Wells Fargo Brandon Couillard | 48%upside $6 | Equal-Weight Downgraded | 8 May 2025 |
Goldman Sachs Matthew Sykes | 98%upside $8 | Buy Maintained | 7 May 2025 |
UBS Lu Li | 73%upside $7 | Neutral Maintained | 7 May 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC
ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) complied with federal securities laws. On May 6, 2025, Myriad Genetics reported first quarter 2025 financial results, and lowered its 2025 financial guidance, revealing, among other things, a decline in pharmacogenomics revenue by 20% year-over-year “due to UnitedHealthcare (UNH) reduc[ing] coverage of GeneSight.” Following this news, the price of the Company's stock dropped.
Neutral
Zacks Investment Research
1 month ago
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
Positive
Zacks Investment Research
1 month ago
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
1 month ago
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing
Neutral
GlobeNewsWire
2 months ago
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators
Neutral
Accesswire
2 months ago
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Neutral
Accesswire
2 months ago
Bronstein, Gewirtz & Grossman, LLC Encourages Myriad Genetics, Inc. (MYGN) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
Neutral
Accesswire
2 months ago
Ongoing Myriad Genetics, Inc. (MYGN) Investigation: Protect Your Rights - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Neutral
Accesswire
2 months ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Myriad Genetics, Inc. (MYGN) And Encourages Shareholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / May 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. ("Myriad Genetics, Inc." or "the Company") (NASDAQ:MYGN). Investors who purchased Myriad Genetics, Inc. securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MYGN.
Neutral
Accesswire
2 months ago
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud
NEW YORK, NY / ACCESS Newswire / May 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning possible violations of federal securities laws. Myriad released its first quarter 2025 financial results on May 6, 2025, revealing "revenue of $196 million declined by 3% year-over-year" and "pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.
Charts implemented using Lightweight Charts™